UniQure’s Huntington’s disease gene therapy AMT-130 continued to show disease-slowing effects at the four-year follow-up, but the company disclosed that the magnitude of benefit has waned versus prior analyses. Analysts highlighted durability questions as the FDA review of UniQure’s marketing application begins, with investors digesting what the change could mean for a regulatory assessment. In parallel, separate reporting noted market reaction to weaker-than-expected durability signals, reflecting how small shifts in long-term endpoints can materially change perceived risk for one-time intracranial gene therapies. For sponsors of similar platforms, UniQure’s disclosure reinforces how persistence of effect can be the central issue in late-stage and submission conversations.